Dr Filippo Pigazzani
Clinical Senior Lecturer Hon Consultant
Molecular and Clinical Medicine, School of Medicine
Consultation and Communication Skills Tutor
Undergraduate Medicine, School of Medicine
Contact
Biography
Dr Pigazanni is clinical research fellow and honorary specialty doctor in cardiology at Ninewells Hospital and Medical School, Dundee. He trained in cardiology at the University of Parma, Italy, where he also did a PhD in Molecular Medicine.
Research
At the moment Dr Pigazanni’s main field of interest is the methodology of clinical trials.
Since May 2017, he has been working on several clinical trials conducted by MEMO Research Unit:
- Febuxostat versus Allopurinol Streamlined Trial (FAST) - a prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of Febuxostat in comparison with Allopurinol in patients with chronic symptomatic hyperuricaemia (>5,706 patients). UK, Denmark, Sweden.
- Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART) – a prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating whether Allopurinol improves cardiovascular outcomes in patients with ischaemic heart disease (>5,215 patients).
- Treatment in Morning vs Evening (TIME) study – an online randomised trial of morning versus evening dosing of antihypertensive medications and cardiovascular outcomes (>21,000 patients).
- Evaluating diuretics in normal care (EVIDENCE) – a cluster randomised evaluation of prescribing policy for hypertension.
Lectures and conferences
October 12-15, 2017, Chicago, IL. “13thAnnual Northwestern Cardiovascular Young Investigators’ Forum”.
Platelet transcriptome profiling in acute myocardial infarction: a potential predictive biomarker?
Stories
Press release
A new study from the University of Dundee has found that hypertension patients who took blood pressure medication at a time aligned with their body clock had a reduced risk of heart attack.